Crescent Biopharma Inc. Common Stock (CBIO)
Stock · NASDAQ · Health Care
$11.79as of 10/16/2026
Price chart
Active signals
CBIO Signal Track Record
How signals performed across all stocks →What CBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 21 | -9.5% | 29% | October 7, 2026 |
| Bollinger Band BreakdownActive now | 20 | +0.1% | 50% | September 23, 2026 |
| Bollinger Band Breakout | 16 | -14.0% | 19% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +13.9% | 75% | August 3, 2026 |
| Any 20-session window (baseline) | -4.8% | 37% |
Computed by MarketWall from daily closing prices since July 10, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CBIO
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commerciali…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 69
- Website
- www.crescentbiopharma.com/
Fundamentals
- 1-day range
- $11.78$12.73
- Market cap
- $610.27M
- P/E (trailing)
- —
- P/E (forward)
- -4.50
- EPS (trailing)
- $-7.41
- Dividend yield
- —
- Beta
- 1.39
- Avg. volume
- 362.0K
How Crescent Biopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Crescent Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CBIOCrescent Biopharma Inc. Common Stock$11.84▼ 5.13%Market cap $610.27MP/E —$8.72$27.41
- NVCTNuvectis Pharma Inc. Common Stock$18.6▼ 1.74%Market cap $613.51MP/E —$5.55$29.28
- MPLTMapLight Therapeutics Inc. Common Stock$7.7▼ 3.99%Market cap $602.19MP/E —$8.7$40.43
- CRMDCorMedix Inc. Common Stock$7.26▼ 2.68%Market cap $589.17MP/E 3.08$6.13$13.02
- FTHFaeth Therapeutics Inc. Common Stock$18.8▼ 8.74%Market cap $632.57MP/E —$13.43$42.14
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CBIO Crescent Biopharma Inc. Common Stock | $610.27M | — | $11.84 | ▼ 5.13% | $8.72$27.41 |
| NVCT Nuvectis Pharma Inc. Common Stock | $613.51M | — | $18.6 | ▼ 1.74% | $5.55$29.28 |
| MPLT MapLight Therapeutics Inc. Common Stock | $602.19M | — | $7.7 | ▼ 3.99% | $8.7$40.43 |
| CRMD CorMedix Inc. Common Stock | $589.17M | 3.08 | $7.26 | ▼ 2.68% | $6.13$13.02 |
| FTH Faeth Therapeutics Inc. Common Stock | $632.57M | — | $18.8 | ▼ 8.74% | $13.43$42.14 |
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027benzinga · 10/15/2026
- HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price TargetBenzinga · 10/6/2026
- Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid TumorsYahoo · 10/5/2026
- Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid TumorsBenzinga · 10/5/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 9/29/2026
- Crescent Biopharma Announces Grants of Inducement AwardsYahoo · 9/25/2026
- The Nascent Crescent Biopharma Thesis: One Year Later And Things Are SteadySeekingAlpha · 9/25/2026
- Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price TargetBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Joshua T. Brumm · September 18, 2026 · Sale7.8K @ $16.71
- Jonathan McNeill · September 18, 2026 · Sale3.8K @ $16.71
- Ryan Lynch · September 16, 2026 · Sale240 @ $17.9
- Jan Pinkas · September 16, 2026 · Sale658 @ $17.9
- Ellie Eunkyung Im · September 16, 2026 · Sale623 @ $17.9
- Richard William Scalzo · September 16, 2026 · Sale568 @ $17.9
- Barbara Harlin Bispham · September 16, 2026 · Sale620 @ $17.9
- Joshua T. Brumm · September 16, 2026 · Sale1.6K @ $17.9
- Jonathan McNeill · September 16, 2026 · Sale731 @ $17.9
- Fairmount Funds Management LLC · July 16, 2026 · Buy853.5K @ $14.5
- Fairmount Funds Management LLC · July 16, 2026 · Buy525.9K @ $14.5
- Ryan Lynch · June 22, 2026 · Sale465 @ $17.99
- Jan Pinkas · June 22, 2026 · Sale1.3K @ $17.99
- Richard William Scalzo · June 22, 2026 · Sale1.1K @ $17.99
- Barbara Harlin Bispham · June 22, 2026 · Sale1.2K @ $17.99
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001
Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.